BrandWikiReturn

List of psychedelic pharmaceutical companies

This is a list of psychedelic pharmaceutical companies, or pharmaceutical companies that are developing psychedelic drugs and/or related drugs such as entactogens, other hallucinogens, or non-hallucinogenic variants (e.g., psychoplastogens) for potential medical use.[1][2] This list also includes individual drug candidates and compounds of psychedelic pharmaceutical companies.[1]

Modern

  • AbbVie – bretisilocin (GM-2505, 5-F-MET; acquired from Gilgamesh Pharmaceuticals)
  • Akome Biotech – AKO-001 (DMT combination), AKO-002 (psilocybin combination), AKO-003 (ketamine combination), AKO-004 (DMT combination)
  • Alexander Shulgin Research Institute (ASRI) – ASR-2001 (2CB-5PrO), ASR-3001 (5-MeO-iPALT)
  • Algernon NeuroScience – DMT (AP-188)
  • Alvarius Pharmaceuticals – 5-MeO-DMT (mebufotenin)
  • Amandala Neuro – psilocin (ELE-101)
  • Apex Labs – psilocybin (APEX-52/90)
  • Arcadia Medicine – non-racemic MDMA (AM-1002), AM-1004, AM-1006
  • Atai Life Sciences (merged with Beckley Psytech) – DMT (VLS-01), (R)-MDMA (EMP-01), ibogaine (IBX-210, DMX-1002), EGX-121, inidascamine (RL-007), EGX-A, EGX-B, arketamine (PCN-101)
  • AtaiBeckley (merger of Atai Life Sciences and Beckley Psytech) – 5-MeO-DMT (mebufotenin, BPL-003), DMT (VLS-01), (R)-MDMA (EMP-01)
  • Awakn Life Sciences (acquired by Solvonis Therapeutics) – ketamine (AWKN-001), MDMA (midomafetamine), esketamine (AWKN-002)
  • Beckley Psytech (merged with Atai Life Sciences) – 5-MeO-DMT (mebufotenin, BPL-003), psilocin (ELE-01)
  • BetterLife Pharma – 2-bromo-LSD (BETR-001, TD-0148A)
  • Biomind Labs – DMT (BMND-01–03), DMT (Triptax), 5-MeO-DMT (mebufotenin, BMND-05/08), BMND007 (DMT or 5-MeO-DMT combination), mescaline (BMND-04/06/09), ibogaine
  • Bright Minds Biosciences – BMB-101, BMB-105, BMB-201, BMB-202, Pharm-136
  • CaaMTech – CT-4201 (psilocin prodrug), TN-001 (via spinout Transneural Therapeutics), TN-002 (via spinout Transneural Therapeutics)
  • Ceruvia Lifesciences – psilocybin (SYNP-101), 2-bromo-LSD (NYPRG-101)
  • Clearmind Medicine – MEAI (CMND-100), 2-FDCK, 3-MMC
  • Clexio Biosciences – esketamine (CLE-100)
  • Compass Pathways – psilocybin (COMP360)
  • Definium Therapeutics (Mind Medicine, MindMed) – LSD (DT120, MM120), (R)-MDMA (MM402), zolunicant (18-MC, MM110), ketanserin (neutralizer), MDMA (midomafetamine), lys-MDA
  • Delix Therapeutics – ibogainalog, tabernanthalog (DLX-007), zalsupindole (DLX-001, AAZ-A-154), DLX-159, DLX-2270, DLX-0002700, JRT
  • DemeRx – ibogaine (IBX-210), noribogaine (DMX-1001)
  • Diamond Therapeutics – psilocybin
  • Eleusis (acquired by Beckley Psytech) – psilocybin (ELE-101, ELE-Psilo), ELE-01 (a phenethylamine), 2C-iBu (ELE-02), ketamine (ELE-Ket)
  • EmpathBio – (R)-MDMA (EMP-01)
  • Engrail Therapeutics – ENX-105, ENX-205
  • Entheon Biomedical – DMT (EBRX-101)
  • Entropy Neurodynamics – psilocybin (TRP-8802), psilocin (TRP-8803)
  • Enveric Biosciences – EB-002 (EB-373; psilocin prodrug), EB-003
  • Equulus Therapeutics – EQL-101 (ibogaine analogue)
  • Filament Health – psilocybin (PEX010)
  • Freedom Biosciences – ketamine/temsirolimus (FREE001)
  • GH Research – 5-MeO-DMT (mebufotenin, GH001–003)
  • Gilgamesh Pharmaceuticals – bretisilocin (GM-2505, 5-F-MET), blixeprodil ((R)-4-FDCK, GM-1020), GM-3009 (an oxa-iboga), GM-5022, GM-2040, oxa-noribogaine, 4-allyl-6-oxa-noribogainalog
  • Helus Pharma (Cybin) – HLP003 (CYB003, deupsilocin), HLP004 (CYB004, deudimethyltryptamine), HLP005 (CYB005), 2C-T-36 (CYB210010), DMT (SPL026), SPL028 (D2-DMT)
  • Incannex Healthcare – psilocybin (PSX-001)
  • Johnson & Johnson – esketamine (Spravato), ITI-1549 (via acquiring Intra-Cellular Therapies)
  • Journey Colab – mescaline (JOUR-5700)
  • Ketabon – oral prolonged-release ketamine (KET01)
  • Küleon Bioscience (Psilosterics) – KB-128
  • Lophora – LPH-5 ((S)-2C-TFM-3PIP), LPH-48
  • Lucid Psycheceuticals – Lucid-PSYCH (Lucid-201)
  • Lusaris Therapeutics – 5-MeO-DMT (mebufotenin)
  • MiHKAL – lys-MDA, SDA, SDMA
  • MindBio Therapeutics – LSD (MB-22001)
  • Mindset Pharma (acquired by Otsuka Pharmaceutical) – MSP-1014 (psilocin prodrug), MSP-2020, MSP-4018, MSP-4019, MSP-4020
  • Mindstate Design Labs – 5-MeO-MiPT (MSD-001), 5-MeO-MiPT combinations (e.g., MSD-101, MSD-201, etc.)
  • MSICS Pharma – psilocybin (MSX-06)
  • Multidisciplinary Association for Psychedelic Studies (MAPS) – MDMA (midomafetamine)
  • MycoMedica Life Sciences – psilocybin (MLS101)
  • Mydecine – psilocybin (MYCO-001/003), MYCO-006, MYCO-007, MYCO-002, MYCO-004, MYCO-005
  • Negev Labs – HBL20016 (5-MeS-6-F-DMT), HBL20017 (4-F-5-MeS-DMT)
  • Neurala Biosciences – DMT/harmala alkaloids (NBX-100, NBX-200)
  • Neurocentrx Pharma – misuse-deterrant oral ketamine (NRCx-201)
  • Ninnion Therapeutics – NIN-S119 (a tryptamine)
  • Nobilis Therapeutics – xenon (NBTX-001)
  • NRx Pharmaceuticals – ketamine (NRX-100)
  • PharmAla Biotech – non-racemic MDMA, MBDB
  • Pilz Bioscience – psilocin (PLZ-1015), baeocystin (PLZ-1019), norpsilocin (PLZ-1017)
  • Psilera – DMT, PSIL-001, PSIL-002, PSIL-006, PSIL-020, PSIL-025, 4-AcO-DMT
  • PsyBio Therapeutics – psilocybin (PB-1818), norbaeocystin
  • Psychae Therapeutics – DMT/β-carboline
  • Psyence Biomedical (Psyence BioMed) – [natural] psilocybin
  • Reconnect Labs – dimethyltryptamine/harmine (RE01), sublingual 5-MeO-DMT (mebufotenin; RE02)
  • Relmada Therapeutics – psilocybin (REL-P11)
  • Reset Pharma – psilocybin (RSTP-1000)
  • Resilient Pharmaceuticals (Lykos Pharmaceuticals, MAPS Public Benefit Corporation) – MDMA (midomafetamine)
  • Reunion Neuroscience (Field Trip Health) – luvesilocin (RE104, FT104, 4-GO-DiPT), RE109 (FT109, 4-GO-DMT), RE245
  • Revive Therapeutics – psilocybin (PSY-0.1–0.6)
  • Scottsdale Research Institute – psilocybin-containing mushrooms
  • Seaport Therapeutics – SPT-348 (2-bromo-LSD prodrug)
  • Seelos Therapeutics – ketamine (Ereska, PMI-100, PMI-150, SLS-002, TUR-002)
  • Sensorium Therapeutics – SNTX-2643 (SENS-01; kanna derivative)
  • Small Pharma (acquired by Cybin/Helus Pharma) – DMT (SPL026), SPL028 (D2-DMT)
  • Solvonis Therapeutics – ketamine (SVN-001), esketamine (SVN-002), SVN-114 (SVN-SDN-14 series), SVN-015
  • Tactogen – MDMA/citalopram, TACT411, TACT523, TACT833, TACT908, 1Z2MAP1O, 1ZP2MA
  • Tasman Therapeutics (spin-out of Douglas Pharmaceuticals) – oral extended-release ketamine (R-107)
  • Terran Biosciences – eplivanserin/volinanserin (trip killer/blocker)
  • Transcend Therapeutics (acquired by Otsuka Pharmaceutical) – methylone (MDMC, TSND-201)
  • Tryp Therapeutics – psilocybin (PFN, TRP-8802–8804, TRYP-0082)
  • Usona Institute – psilocybin, 5-MeO-DMT (mebufotenin), bufotenin (5-HO-DMT)
  • Xylo (Psylo) – XYL-1001 (PSYLO-1001), XYL-1002 (PSYLO-1002), XYL-3001 (PSYLO-3001), XYL-4001 (PSYLO-4001), XYL-5001 (PSYLO-5001)

Premodern

  • Bristol-Myers Company – (R)-Ariadne ((R)-4C-DOM, BL-3912A, Dimoxamine)
  • Dow Chemical Company – DOM (K-61,082), DOET
  • Merck – MDMA, mescaline
  • Sandoz – LSD (LSD-25, lysergide, Delysid), psilocybin (CY-39, Indocybin), psilocin (CX-59), ethocybin (CEY-19), 4-HO-DET (CZ-74), others
  • Smith, Kline & French – MDA (SKF-5, Amphedoxamine), 3-APBT (SKF-6678)
  • Soviet Union – α-methyltryptamine (AMT, Indopan)
  • Upjohn – α-ethyltryptamine (AET, etryptamine, Monase)

See also

  • List of investigational hallucinogens and entactogens
  • List of psychedelic chemists
  • List of psychedelic drugs
  • Psychedelic Alpha

External links

References

  1. Psychedelic Companies Directory Psychedelic Alpha, 9 August 2024, retrieved 13 April 2026^
  2. Carina S Peritore. The Promise of Psychedelic Research Future Drug Discovery, 2022, retrieved 13 April 2026^